Literature DB >> 22228164

Pathological evaluation of mesocolic resection quality and ex vivo methylene blue injection: what is the impact on lymph node harvest after colon resection for cancer?

Matteo Frasson1, Carmen Faus, Alvaro Garcia-Granero, Ramon Puga, Blas Flor-Lorente, Andres Cervantes, Samuel Navarro, Eduardo Garcia-Granero.   

Abstract

BACKGROUND: Although the National Quality Forum has endorsed the harvest of ≥12 lymph nodes as a standard quality indicator for colon cancer surgery, this minimum quantity is not reached in many centers.
OBJECTIVE: The aim of this study was to assess the impact of the implementation of a mesocolon evaluation pathological protocol and ex vivo arterial methylene blue injection on the number of nodes harvested after colon cancer resection.
DESIGN: A prospective series was compared with a historical group. SETTINGS: This study was conducted by a specialized colorectal multidisciplinary team at a tertiary teaching hospital. PATIENTS: From June 2009 to December 2009, all the specimens after colon resection for cancer were analyzed with the use of a "mesocolon quality pathological evaluation" protocol. Moreover, a consecutive series of specimens was analyzed after arterial ex vivo injection of methylene blue. We compared the study groups with our previous series (2005-2009).
INTERVENTIONS: The "mesocolon quality pathological evaluation" protocol was used with or without arterial methylene blue ex vivo injection. MAIN OUTCOME MEASURE: The primary outcome measure was the number of lymph nodes harvested.
RESULTS: The mean number (SD) of lymph nodes collected was 20.6 (10.5), 37.1 (12.8), and 47.6 (12.9) (p < 0.0001) in the control, protocol, and methylene blue groups. In the control group, the minimum number of 12 and 18 lymph nodes collected was not reached in 92 (15.9%) and 258 (44.6%) patients. In contrast, all patients in the protocol and methylene blue groups had more than 18 lymph nodes collected. The multivariate analysis confirmed the application of the "mesocolon quality pathological evaluation" protocol and the methylene blue ex vivo injection, along with the type of resection and the length of the specimen, to be independent factors determining the number of nodes collected. LIMITATIONS: The patients are not randomly selected and are compared with a retrospective series.
CONCLUSION: The implementation of a "mesocolon quality pathological evaluation" protocol along with the arterial ex vivo injection of methylene blue can significantly increase the number of nodes isolated after colonic resection, reaching a 100% rate of specimens with more than 12 nodes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228164     DOI: 10.1097/DCR.0b013e31823bd9c1

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  5 in total

1.  Extended lymphadenectomy in colon cancer is debatable.

Authors:  Jamie Murphy; Tonia Young-Fadok
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

2.  The fusion fascia of Fredet: an important embryological landmark for complete mesocolic excision and D3-lymphadenectomy in right colon cancer.

Authors:  Alvaro Garcia-Granero; Gianluca Pellino; Matteo Frasson; Delfina Fletcher-Sanfeliu; Fernando Bonilla; Luis Sánchez-Guillén; Alberto Domenech Dolz; Vicent Primo Romaguera; Luis Sabater Ortí; Francisco Martinez-Soriano; Eduardo Garcia-Granero; Alfonso A Valverde-Navarro
Journal:  Surg Endosc       Date:  2019-05-28       Impact factor: 4.584

Review 3.  Stage migration vs immunology: The lymph node count story in colon cancer.

Authors:  Bruno Märkl
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

4.  The prognostic significance of lymph node size in node-positive colon cancer.

Authors:  Philipp Schrembs; Benedikt Martin; Matthias Anthuber; Gerhard Schenkirsch; Bruno Märkl
Journal:  PLoS One       Date:  2018-08-10       Impact factor: 3.240

5.  Role of methylene blue in detecting the sentinel lymph node in colorectal cancer: In vivo vs. ex vivo technique.

Authors:  Daniel Staniloaie; Constantin Budin; Danut Vasile; George Iancu; Alexandru Ilco; Daniel Iulian Voiculescu; Alexandra Florina Trandafir; Tarek Ammar; Emel Suliman; Emine Suliman; Dorin Dragoş; Maria-Daniela Tanasescu
Journal:  Exp Ther Med       Date:  2021-11-24       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.